SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants

References

• Callow KA, Parry HF, Sergeant M, et al. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435–446.
   PubMed Web of Science ®Google Scholar
• Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med [Internet]. 2020;26:1691–1693. doi:10.1038/s41591-020-1083-1.
   PubMed Web of Science ®Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol [Internet]. 2020;5:1598–1607. doi:10.1038/s41564-020-00813-8.
   PubMed Web of Science ®Google Scholar
• Haveri A, Ekström N, Solastie A, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021;51:3202–3213.
   PubMed Web of Science ®Google Scholar
• Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature [Internet]. 2021;595:421–425. doi:10.1038/s41586-021-03647-4.
   Google Scholar
• Payne DC, Iblan I, Rha B, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22:1824–1826.
   PubMed Web of Science ®Google Scholar
• Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity [Internet]. 2020;53:248–263. doi:10.1016/j.immuni.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Tan C-W, Chia W-N, BE Y, et al. Pan-Sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N Engl J Med. 2021;385:1401–1406.
   PubMed Web of Science ®Google Scholar
• León TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis — California and New York, May – November 2021. Morb Mortal Wkly Rep. 2022;71:125–131
   PubMed Web of Science ®Google Scholar
• Arcari C, Croisant S, Kirschbaum M, et al. Population health strategic plan. Univ. Texas Med. Branch. 2017:1–43.
   Google Scholar
• Center for Disease Control and Prevention. COVID-19 vaccinations in the United States, County [Internet]. 2022 [cited 2022 Feb 15]. https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-County/8xkx-amqh.
   Google Scholar
• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis [Internet]. 2020;20:533–534. doi:10.1016/S1473-3099(20)30120-1.
   PubMed Web of Science ®Google Scholar
• Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: A systematic review and pooled analysis. Cureus. 2021;13:e19102.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N Engl J Med [Internet]. 2021;385:2585–2586. http://www.nejm.org/doi/10.1056NEJMc2110300.
   PubMed Web of Science ®Google Scholar
• Alejo JL, Mitchell J, Chang A, et al. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. Jama. 2022;327:1085–1087.
   PubMed Web of Science ®Google Scholar
• Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural- and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;3099:7–12.
   Google Scholar
• Lau SKP, Li KSM, Tsang AKL, et al. Genetic characterization of betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus Bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol. 2013;87:8638–8650.
   PubMed Web of Science ®Google Scholar
• Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science (80-). 2020;370:89–94.
   PubMed Web of Science ®Google Scholar
• Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature [Internet]. 2020;584:457–462. doi:10.1038/s41586-020-2550-z.
   Google Scholar
• Kundu R, Narean JS, Wang L, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022;13:1–8.
   PubMedGoogle Scholar
• Pedersen J, Koumakpayi IH, Babuadze G, et al. Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product. Sci Rep [Internet]. 2022;12:1–7. doi:10.1038/s41598-022-17241-9.
   PubMed Web of Science ®Google Scholar
• Silva EKVB, Bomfim CG, Barbosa AP, et al. Immunization with SARS-CoV-2 nucleocapsid protein triggers a pulmonary immune response in rats. Omri A, editor. PLoS One [Internet]. 2022;17:e0268434. Available from: https://dx.plos.org/10.1371journal.pone.0268434.
   PubMedGoogle Scholar
• Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science (80-) [Internet]. 2022;1841:1–23. Available from: https://www.science.org/doi/10.1126science.abq1841.
   Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature [Internet]. 2022; Available from: https://www.nature.com/articles/s41586-022-04980-y.
   Google Scholar
• Lozano-Ojalvo D, Camara C, Lopez-Granados E, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity innaïvee and COVID-19 recovered individuals. Cell Rep. 2021;36:109570.
   PubMed Web of Science ®Google Scholar
• Mazzoni A, Lauria N, Di ML, et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021;131:e149150.
   PubMed Web of Science ®Google Scholar
• Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1372–1374.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Gagne M, Wagner DA, et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates. Science (80-). 2021;374:1343–1353.
   PubMed Web of Science ®Google Scholar
• Gagne M, Moliva JI, Foulds KE, et al. 2022 mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell [Internet]. 2022;185:1556–1571. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867422003889.
   Google Scholar
• Chalkias S, Harper C, Vrbicky K, et al. A bivalent Omicron-containing booster vaccine against COVID-19. N Engl J Med [Internet]. 2022;25:1–23. Available from: http://www.nejm.org/doi/10.1056NEJMoa2208343.
   Google Scholar
• Callaway E. New Omicron-specific vaccines offer similar protection to existing boosters. Nature [Internet]. 2022;609:232–233. Available from: https://www.nature.com/articles/d41586-022-02806-5.
   Google Scholar
• Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136–2143.
   PubMed Web of Science ®Google Scholar
• Franke C, Ferse C, Kreye J, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun [Internet]. 2021;93:415–419. Available from: https://linkinghub.elsevier.com/retrieve/pii/S088915912032465X.
   PubMed Web of Science ®Google Scholar
• Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131:e154886.
   PubMed Web of Science ®Google Scholar
• Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283–288.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ebinger JE, Mostafa R, et al. The evidence base for physiotherapy in myalgic encephalomyelitis/chronic fatigue syndrome when considering post-exertional malaise: a systematic review and narrative synthesis. J Transl Med [Internet]. 2021;19:1–13. doi:10.1186/s12967-021-03184-8.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Qiu X, McCorrister S, et al. Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep. 2017;7:1–11.
   PubMed Web of Science ®Google Scholar
• Wan SW, Lin CF, Yeh TM, et al. Autoimmunity in dengue pathogenesis. J Formos Med Assoc. 2013;112:3–11.
   PubMed Web of Science ®Google Scholar
• Nico D, Conde L, Rivera-Correa JL, et al. Prevalence of IgG Autoantibodies against GD3 Ganglioside in acute Zika virus infection. Front Med [Internet]. 2018;5, Available from: http://journal.frontiersin.org/article/10.3389fmed.2018.00025/full.
   PubMed Web of Science ®Google Scholar
• Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates Among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence — 25 U.S. jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2022;71:132–138. Available from: http://www.cdc.gov/mmwr/volumes/71/wr/mm7104e2.htm?s_cid = mm7104e2_w.
   PubMedGoogle Scholar